232 related articles for article (PubMed ID: 24447144)
1. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase.
Stoevesandt J; Hain J; Stolze I; Kerstan A; Trautmann A
Clin Exp Allergy; 2014; 44(5):747-55. PubMed ID: 24447144
[TBL] [Abstract][Full Text] [Related]
2. Hymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective.
Stoevesandt J; Hosp C; Kerstan A; Trautmann A
Ann Allergy Asthma Immunol; 2015 May; 114(5):411-6. PubMed ID: 25952636
[TBL] [Abstract][Full Text] [Related]
3. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
Ruëff F; Vos B; Oude Elberink J; Bender A; Chatelain R; Dugas-Breit S; Horny HP; Küchenhoff H; Linhardt A; Mastnik S; Sotlar K; Stretz E; Vollrath R; Przybilla B; Flaig M
Clin Exp Allergy; 2014; 44(5):736-46. PubMed ID: 24447114
[TBL] [Abstract][Full Text] [Related]
4. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy.
White KM; England RW
Ann Allergy Asthma Immunol; 2008 Oct; 101(4):426-30. PubMed ID: 18939733
[TBL] [Abstract][Full Text] [Related]
5. Changing practice: no need to stop ACE inhibition for venom immunotherapy.
Slade CA; Douglass JA
Clin Exp Allergy; 2014; 44(5):617-9. PubMed ID: 24734926
[No Abstract] [Full Text] [Related]
6. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability during build-up phase of a rush venom immunotherapy.
Bernkopf K; Rönsch H; Spornraft-Ragaller P; Neumeister V; Bauer A
Ann Allergy Asthma Immunol; 2016 Apr; 116(4):360-5. PubMed ID: 27055991
[TBL] [Abstract][Full Text] [Related]
8. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
Spoerl D; Bircher AJ; Scherer K
J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
[TBL] [Abstract][Full Text] [Related]
10. β-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy.
Sturm GJ; Herzog SA; Aberer W; Alfaya Arias T; Antolín-Amérigo D; Bonadonna P; Boni E; Bożek A; Chełmińska M; Ernst B; Frelih N; Gawlik R; Gelincik A; Hawranek T; Hoetzenecker W; Jiménez Blanco A; Kita K; Kendirlinan R; Košnik M; Laipold K; Lang R; Marchi F; Mauro M; Nittner-Marszalska M; Poziomkowska-Gęsicka I; Pravettoni V; Preziosi D; Quercia O; Reider N; Rosiek-Biegus M; Ruiz-Leon B; Schrautzer C; Serrano P; Sin A; Sin BA; Stoevesandt J; Trautmann A; Vachová M; Arzt-Gradwohl L
Allergy; 2021 Jul; 76(7):2166-2176. PubMed ID: 33605465
[TBL] [Abstract][Full Text] [Related]
11. Venom Immunotherapy in High-Risk Patients: The Advantage of the Rush Build-Up Protocol.
Rosman Y; Confino-Cohen R; Goldberg A
Int Arch Allergy Immunol; 2017; 174(1):45-51. PubMed ID: 28950273
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.
González de Olano D; Alvarez-Twose I; Esteban-López MI; Sánchez-Muñoz L; de Durana MD; Vega A; García-Montero A; González-Mancebo E; Belver T; Herrero-Gil MD; Fernández-Rivas M; Orfao A; de la Hoz B; Castells MC; Escribano L
J Allergy Clin Immunol; 2008 Feb; 121(2):519-26. PubMed ID: 18177694
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of a 3-Day Rush Insect Venom Immunotherapy Protocol.
Kranert P; Forchhammer S; Volc S; Stenger F; Schaller M; Fischer J
Int Arch Allergy Immunol; 2020; 181(2):111-118. PubMed ID: 31794966
[TBL] [Abstract][Full Text] [Related]
14. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B;
J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
[TBL] [Abstract][Full Text] [Related]
15. Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment.
Bilò MB
Allergy; 2011 Jul; 66 Suppl 95():35-7. PubMed ID: 21668850
[TBL] [Abstract][Full Text] [Related]
16. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
[TBL] [Abstract][Full Text] [Related]
17. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema.
Stoevesandt J; Hain J; Kerstan A; Trautmann A
J Allergy Clin Immunol; 2012 Sep; 130(3):698-704.e1. PubMed ID: 22554708
[TBL] [Abstract][Full Text] [Related]
18. Clinical aspects of hymenoptera venom allergy and venom immunotherapy.
Bilò MB; Tontini C; Martini M; Corsi A; Agolini S; Antonicelli L
Eur Ann Allergy Clin Immunol; 2019 Nov; 51(6):244-258. PubMed ID: 31594296
[TBL] [Abstract][Full Text] [Related]
19. Rush Venom Immunotherapy in Children.
Confino-Cohen R; Rosman Y; Goldberg A
J Allergy Clin Immunol Pract; 2017; 5(3):799-803. PubMed ID: 27914814
[TBL] [Abstract][Full Text] [Related]
20. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety.
Kalogeromitros D; Makris M; Koti I; Chliva C; Mellios A; Avgerinou G; Theoharides TC
Allergol Immunopathol (Madr); 2010; 38(2):69-73. PubMed ID: 19853357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
